Related content

Safety and Tolerability of the Dual 5 -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

By Andriole G.L.   Kirby R.  

European Urology, Vol. 44, Iss. 1, 2003-07 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

By Roehrborn C.G.   Boyle P.   Nickel J.C.   Hoefner K.   Andriole G.   the ARIA3001 ARIA3002 and ARIA3003 Study Investigators  

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 434-441

Elsevier

Access to resources Recommend Favorite

Nocturia and benign prostatic hyperplasia

By Yoshimura K.   Ohara H.   Ichioka K.   Terada N.   Matsui Y.   Terai A.   Arai Y.  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 786-790

Elsevier

Access to resources Recommend Favorite

Increased Bladder Apoptosis with α-1 Adrenoceptor Antagonists in Benign Prostatic Hyperplasia

By Erdoğru T.   Gülkesen K. H.   Kukul E.   Yalçinkaya M.   Karpuzoğlu G.   Baykara M.  

Scandinavian Journal of Urology and Nephrology, Vol. 36, Iss. 3, 2002-06 ,pp. : 188-193

Informa Healthcare

Access to resources Recommend Favorite

Estrogen Receptors in the Human Male Prostatic Urethra and Prostate in Prostatic Cancer and Benign Prostatic Hyperplasia

By Bødker Anders   Bruun Jens   Balslev Eva   Iversen Hans-Georg   Meyhoff Hans-Henrik   Andersson Karl-Erik  

Scandinavian Journal of Urology and Nephrology, Vol. 33, Iss. 4, 1999-09 ,pp. : 237-242

Informa Healthcare

Access to resources Recommend Favorite